| |

24 February 2025: PIB Summary For UPSC

Get Your PDF

1. Union Health Ministry takes immediate action in response to concerns on export of unapproved drug combination of Tapentadol and Carisoprodol

(Source – https://pib.gov.in/PressReleasePage.aspx?PRID=2105672 )

Topic: GS2 – Social justice – Health
Context
  • The government banned the export of Tapentadol-Carisoprodol combination due to its unapproved status in India, raising safety concerns.

About Tapentadol and Carisoprodol:

  • Tapentadol: It is an opioid analgesic used for treating moderate to severe pain.
  • It works by binding to opioid receptors and inhibiting norepinephrine reuptake, providing dual-action pain relief.
  • It is available in immediate-release (50, 75, and 100 mg) and extended-release (100, 150, and 200 mg) tablet forms.
  • Carisoprodol: It is a centrally acting muscle relaxant used to relieve musculoskeletal pain and discomfort.
  • It acts on the brain and spinal cord to suppress nerve signals causing pain.
  • The combination of Tapentadol and Carisoprodol is not approved in India due to safety concerns.

Why has the government banned the export?

  • Aveo Pharmaceuticals exported these drugs without proper authorization, violating regulatory norms.
  • A CDSCO audit revealed non-compliance, leading to a stop activity order and seizure of 1.3 crore tablets.
  • The ban ensures public safety, prevents misuse, and upholds pharmaceutical industry standards.

Check Out 22 February 2025: PIB Summary For UPSC

Similar Posts